Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 1, 2012, Pages 112-116

  Kotani, H ^a   Kishi, R ^a   Mouri, A ^a   Sashio, T ^b   Shindo, J ^c   Shiraki, A ^c   Hiramatsu, T ^d   Iwata, S ^d   Taniguchi, H ^e   Nishiyama, O ^e   Iwata, M ^f   Suzuki, R ^g   Gonda, H ^g   Niwa, T ^h   Kondo, M ^h   Hasegawa, Y ^h   Kume, H ⁱ   Noda, Y ^a  

^a MEIJO UNIVERSITY   (Japan)

^b CHUKYO HOSPITAL   (Japan)

^c OGAKI MUNICIPAL HOSPITAL   (Japan)

^d KOMAKI CITY HOSPITAL   (Japan)

^e TOSEI GENERAL HOSPITAL   (Japan)

^f Kariya Toyota General Hospital   (Japan)

^g TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KINKI UNIVERSITY   (Japan)

Author keywords

genetic polymorphisms; Japanese patients; pharmacogenetics

Indexed keywords

ALOX5 PROTEIN; DNA; LEUKOTRIENE; LTA4H PROTEIN; MONTELUKAST; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; POPULATION; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACETATES; ADULT; AGED; ALLELES; ANTI-ASTHMATIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ASIAN CONTINENTAL ANCESTRY GROUP; ASTHMA; EPOXIDE HYDROLASES; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; JAPAN; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84856350609     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01248.x     Document Type: Article

References (28)

1. Bousquet J, Van Cauwenberge P, Khaltaev N,. Allergic rhinitis and its impact on asthma. Journal of Allergy and Clinical Immunology, 2001; 108: 134-147.
2. Drazen JM,. Leukotrienes as mediators of airway obstruction. American Journal of Respiratory and Critical Care Medicine, 1998; 158: 193-200.
3. Kanaoka Y, Boyce JA,. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. Journal of Immunology, 2004; 173: 1503-1510. (Pubitemid 38971578)
4. Misson J, Clark W, Kendall MJ,. Therapeutic advances: leukotriene antagonists for the treatment of asthma. Journal of Clinical Pharmacy and Therapeutics, 1999; 24: 17-22. (Pubitemid 29171675)
5. Duroudier NP, Tulah AS, Sayers I,. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy, 2009; 64: 823-839.
6. Busse WW, Kraft M,. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest, 2005; 127: 1312-1326. (Pubitemid 46224296)
7. Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. American Journal of Respiratory and Critical Care Medicine, 2001; 163: 226-233. (Pubitemid 32095274)
8. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D'Orazio N,. Antileukotriene drugs: clinical application, effectiveness and safety. Current Medicinal Chemistry, 2007; 14: 1966-1977. (Pubitemid 47209107)
9. Dicpinigaitis PV,. Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. Chest, 2006; 129: 75-79.
10. Drazen JM, Israel E, O'Byrne PM,. Treatment of asthma with drugs modifying the leukotriene pathway. New England Journal of Medicine, 1999; 340: 197-206. (Pubitemid 29063217)
11. Spector SL, Tan RA,. Effectiveness of montelukast in the treatment of cough variant asthma. Annals of Allergy, Asthma & Immunology, 2004; 93: 232-236. (Pubitemid 39280525)
12. Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O'byrne P, Sheffer A,. GINA guidelines on asthma and beyond. Allergy, 2007; 62: 102-112. (Pubitemid 46091634)
13. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal, 2008; 31: 143-178.
14. Bousquet J, Demoly P, Humbert M,. Montelukast in guidelines and beyond. Advances in Therapy, 2009; 26: 575-587.
15. Mclvor RA, Kaplan A, Koch C, Sampalis JS,. Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial. Canadian Respiratory Journal, 2009; 16: 11-21.
16. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. Journal of Allergy and Clinical Immunology, 2002; 110: 847-854. (Pubitemid 36005870)
17. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. Journal of Allergy and Clinical Immunology, 2005; 115: 233-242. (Pubitemid 40215084)
18. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. American Journal of Respiratory and Critical Care Medicine, 2006; 173: 379-385. (Pubitemid 43228324)
19. Zhang J, Paré PD, Sandford AJ,. Recent advances in asthma genetics. Respiratory Research, 2008; 9, 4.
20. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST,. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenetics and Genomics, 2009; 19: 244-247.
21. Sunyer J, Antõ JM, Kogevinas M, et al. Risk factors for asthma in young adults. Spanish Group of the European Community Respiratory Health Survey. European Respiratory Journal, 1997; 10: 2490-2494.
22. Isidoro GM, Davila I, Moreno E, Laffond E, Lorente F, González SR,. IL4RA gene polymorphism (Q576R) is associated with higher total IgE levels in Spanish patients with family history of atopy. Medicina Clinica, 2005; 124: 211-222.
23. Smits KM, Schouten JS, Smits LJ, Stelma FF, Nelemans P, Prins MH,. A review on the design and reporting of studies on drug-gene interaction. Journal of Clinical Epidemiology, 2005; 58: 651-654. (Pubitemid 40797893)
24. Holloway JW, Barton SJ, Holgate ST, Rose-Zerilli MJ, Sayers I,. The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility. Allergy, 2008; 63: 1046-1053.
25. Montuschi P, Martello S, Felli M, Mondino C, Barnes PJ, Chiarotti M,. Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic children. Respiratory Research, 2005; 6: 119.
26. Wenzel SE,. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy, 1997; 17: 3-12.
27. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS, van den Oord EJ, Anderson WH,. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenetics and Genomics, 2007; 17: 189-196. (Pubitemid 46668003)
28. Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, Feldman MW,. Genetic structure of human populations. Science, 2002; 298: 2381-2385. (Pubitemid 36014209)